Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $75 price target on Crispr Therapeutics, and added that Crispr remains a top pick for 2019, after the company announced the expansion of its wholly-owned allogeneic CAR-T pipeline at the American Association for Cancer Reseach, or AACR. Tenthoff said he expects more preclinical CAR-T data at the American Society of Gene and Cell Therapy, or ASGCT, in April. The analyst believes the biggest driver for the company remains “first-in-man Phase I/II CTX001 data in Beta-thal and potentially Sickle Cell Disease” this year.
https://thefly.com/landingPageNews.php?id=2887545
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.